Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.

BACKGROUND & AIMS Hepatic encephalopathy (HE) is a serious complication of cirrhosis and is associated with gut dysbiosis. Proton pump inhibitors (PPIs), frequently prescribed to patients with cirrhosis, can contribute to small-bowel bacterial overgrowth. We investigated whether PPI predisposes patients with cirrhosis to HE using a large database of patients. METHODS We performed a case-control study nested within a sample of Taiwan National Health Insurance beneficiaries (n = 1,000,000), followed up longitudinally from 1998 through 2011. Patients with cirrhosis and an occurrence of HE (n = 1166) were selected as the case cohort and matched to patients without HE (1:1, controls) for sex, enrollment time, end point time, follow-up period, and advanced cirrhosis. Information on prescribed drugs, drug dosage, supply days, and numbers of dispensed pills was extracted from the Taiwan National Health Insurance database. PPI use was defined as more than 30 cumulative defined daily doses (cDDDs); PPI nonuse was defined as 30 cDDDs or fewer. We performed logistic regression analyses to estimate the association between PPI use and the occurrence of HE. RESULTS Among patients with cirrhosis and an occurrence of HE, 38% (n = 445) had a history of PPI use before HE occurrence. We observed a relationship between dose of PPI taken and HE risk. The confounder-adjusted odd ratios were 1.41 (95% confidence interval [CI], 1.09-1.84), 1.51 (95% CI, 1.11-2.06), and 3.01 (95% CI, 1.78-5.10) for patients with 30-120 cDDDs, 120-365 cDDDs, and more than 365 cDDDs, respectively, compared with PPI nonusers. All categories of PPIs, except rabeprazole, were associated with an increased risk of HE. CONCLUSIONS Based on an analysis of data from Taiwan National Health Insurance beneficiaries, we found that use of PPIs in patients with cirrhosis increases the risk for HE; risk increases with dose. It therefore is important for health care providers to carefully consider prolonged PPI use by patients with cirrhosis.

[1]  Karl Broich,et al.  Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. , 2016, JAMA neurology.

[2]  P. Tandon,et al.  Fecal microbiota transplantation in the management of hepatic encephalopathy , 2016, Hepatology.

[3]  Tim D Spector,et al.  Proton pump inhibitors alter the composition of the gut microbiota , 2015, Gut.

[4]  Jingyuan Fu,et al.  Proton pump inhibitors affect the gut microbiome , 2015, Gut.

[5]  Nora C. Toussaint,et al.  Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. , 2015, Gastroenterology.

[6]  F. Jessen,et al.  Risk of dementia in elderly patients with the use of proton pump inhibitors , 2015, European Archives of Psychiatry and Clinical Neuroscience.

[7]  B. Kronenberger,et al.  Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis , 2015, Alimentary pharmacology & therapeutics.

[8]  M. Merli,et al.  The chronic use of beta‐blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[9]  Philip Wong,et al.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver , 2014, Hepatology.

[10]  B. Sharma,et al.  Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  Andmorgan R. Fisher,et al.  Altered profile of human gut microbiome is associated with cirrhosis and its complications. , 2014, Journal of hepatology.

[12]  J. Bajaj.  The role of microbiota in hepatic encephalopathy , 2014, Gut microbes.

[13]  E. di Giulio,et al.  Proton pump inhibitor therapy and potential long-term harm , 2014, Current opinion in endocrinology, diabetes, and obesity.

[14]  J. Hughes,et al.  Proton Pump Inhibitor–Associated Hypomagnesemia: What Do FDA Data Tell Us? , 2013, The Annals of pharmacotherapy.

[15]  Walter Wai-Yip Chan,et al.  Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  Jaw-Town Lin,et al.  Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. , 2012, JAMA.

[17]  K. Lapane,et al.  Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis , 2012, Alimentary pharmacology & therapeutics.

[18]  Samir Samman,et al.  Vitamin B12 status, cognitive decline and dementia: a systematic review of prospective cohort studies , 2012, British Journal of Nutrition.

[19]  I. Boin,et al.  Correlation between serum magnesium levels and hepatic encephalopathy in immediate post liver transplantation period. , 2012, Transplantation proceedings.

[20]  Anil K. Jain,et al.  Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  H. Dupont,et al.  Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection , 2011, Alimentary pharmacology & therapeutics.

[22]  A. Zinsmeister,et al.  Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture , 2011, Alimentary pharmacology & therapeutics.

[23]  Kyeong Ok Kim,et al.  Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites , 2011, Scandinavian journal of gastroenterology.

[24]  R. Butterworth.  Hepatic encephalopathy: A central neuroinflammatory disorder? , 2011, Hepatology.

[25]  Ching-Lan Cheng,et al.  Validation of the national health insurance research database with ischemic stroke cases in Taiwan , 2011, Pharmacoepidemiology and drug safety.

[26]  Y. Chawla,et al.  Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. , 2010, Journal of hepatology.

[27]  Jaw-Town Lin,et al.  Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. , 2010, Gastroenterology.

[28]  R. Jensen,et al.  Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium , 2010, Current gastroenterology reports.

[29]  R. Prakash,et al.  Mechanisms, diagnosis and management of hepatic encephalopathy , 2010, Nature Reviews Gastroenterology &Hepatology.

[30]  S. Hamid,et al.  Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis. , 2010, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[31]  C. Leevy,et al.  Rifaximin treatment in hepatic encephalopathy. , 2010, The New England journal of medicine.

[32]  B. Gómez-Anson,et al.  Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis , 2009, The American Journal of Gastroenterology.

[33]  R. Hoffmann,et al.  Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites , 2009, The American Journal of Gastroenterology.

[34]  R. Jalan,et al.  Review article: hyperammonaemic and catabolic consequences of upper gastrointestinal bleeding in cirrhosis , 2009, Alimentary pharmacology & therapeutics.

[35]  E. Björnsson,et al.  Inadequate use of proton-pump inhibitors in patients with liver cirrhosis , 2008, European journal of gastroenterology & hepatology.

[36]  F. Azzaroli,et al.  Proton pump inhibitors in cirrhosis: tradition or evidence based practice? , 2008, World journal of gastroenterology.

[37]  A. Sanyal,et al.  Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis , 2007, The American Journal of Gastroenterology.

[38]  A. Sanyal,et al.  Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. , 2007, The American journal of gastroenterology.

[39]  Ritesh Agarwal,et al.  Lactulose improves cognitive functions and health‐related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy , 2007, Hepatology.

[40]  B. Batuwitage,et al.  Inappropriate prescribing of proton pump inhibitors in primary care , 2007, Postgraduate Medical Journal.

[41]  N. Shaheen,et al.  Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: A randomized, controlled trial , 2005, Hepatology.

[42]  C. Sakamoto,et al.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[43]  M. Uribe,et al.  Hepatic encephalopathy: a review. , 2003, Annals of hepatology.

[44]  Y. Naito,et al.  A new mechanism for anti‐inflammatory actions of proton pump inhibitors – inhibitory effects on neutrophil–endothelial cell interactions , 2000, Alimentary pharmacology & therapeutics.

[45]  T. Ishizaki,et al.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.

[46]  N. Assy,et al.  Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. , 1999, Gastrointestinal endoscopy.

[47]  E. Strauss,et al.  The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis. , 1998, Hepato-gastroenterology.

[48]  S. O'keefe,et al.  Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole , 1996, Alimentary pharmacology & therapeutics.

[49]  M. Merli,et al.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt , 1996, Digestive Diseases and Sciences.

[50]  S. Binkley,et al.  Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. , 1996, Pharmacogenetics.

[51]  Kaoru Kobayashi,et al.  Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S‐mephenytoin 4′‐hydroxylation status , 1995, Clinical pharmacology and therapeutics.

[52]  G. Marchesini,et al.  Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross‐over comparison , 1993, Journal of internal medicine.

[53]  E. Strauss,et al.  Bacterial infections associated with hepatic encephalopathy: prevalence and outcome. , 2003, Annals of hepatology.

[54]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.